Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis.
An analysis is presented to compare the efficacies of the doxazosin gastrointestinal therapeutic system (doxazosin-GITS) and tamsulosin in patients with benign prostatic hyperplasia (BPH), collecting data from a published 20-week, randomized, double-blind, crossover study. Results demonstrated that after 8 weeks of treatment, both doxazosin-GITS and tamsulosin provided significant (p < 0.001) improvement from baseline in total international prostate symptom score (IPSS) and obstructive and irritative subscores. Doxazosin-GITS was more effective than tamsulosin (p = 0.019 between-group difference for total IPSS; p = 0.001 for irritative subscore). Similarly, after the first 4 weeks of treatment, prior to dose titration, both doxazosin-GITS and tamsulosin provided significant (p < or = 0.001) improvement in total IPSS and subscores. Doxazosin-GITS was more effective than tamsulosin (p = 0.045 between-group difference for obstructive subscore). These data confirm that the efficacy of doxazosin is superior to that of tamsulosin in the management of patients with BPH.
Department of Urology Research, Ingleby House, St. George's Hospital, Blackshaw Road, London, UK. rogerkirby@compuserve.com
R S
RS
Kirby
S
S
Quinn
S
S
Mallen
D
D
Jensen
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000368:Aged; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D017292:Doxazosin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin; D016896:Treatment Outcome
D000317:Adrenergic alpha-Antagonists; D003692:Delayed-Action Preparations; D013449:Sulfonamides; D000077409:Tamsulosin; D017292:Doxazosin